Ono Pharmaceutical

A series of dice with a bag on them illustrating cost cuts

Cue lays off 25%, prioritizing preclinical autoimmune assets

Prioritizing the preclinical autoimmune programs means two IL-2-based cancer drugs—which are both in human trials—are being placed on the back burner.

James Waldron Jul 26, 2024 4:29am

Graphic image of a cardboard box delivered to a doorstep with a welcome mat

Equillium delivers new lupus data to Ono's doorstep

Apr 1, 2024 10:53am

pay deal hand over cash licensing transaction money

Ono taps Shattuck for $227M bifunctional fusion protein deal

Feb 13, 2024 8:29am

photo of two people shaking hands one of which has red nail polish on

Japan's Ono signs up for KSQ's preclinical cancer programs

Jan 25, 2023 9:55am

Equillium is no longer buying Metacrine, citing new cash

Dec 27, 2022 4:00pm

Ono inks deal for antibody against ‘very challenging’ I-O target

Mar 31, 2022 7:58am